Newly identified biomarker may predict NSCLC patients' treatment response to chemoimmunotherapy

Cutting-edge cancer treatments like immunotherapy are offering new hope for patients, often in combination with more common approaches such as chemotherapy. But determining the best treatment combination isn't always straightforward.

Related Keywords

Emily Henderson ,Fumito Ito ,Cancer Research Communications ,Norris Comprehensive Cancer Center ,Clinical Science Research ,Keck School Of Medicine ,Comprehensive Cancer Center ,Cancer Research ,Keck School ,Eacht Cell ,Biomarker ,Research ,Flood ,Blood Test ,Dancer ,Fell ,Chemotherapy ,Immunotherapy ,Lung Cancer ,Medicine ,Non Small Cell Lung Cancer ,Small Cell Lung Cancer ,T Cell ,Humor ,